Global pharmaceutical sales hit a record $1 trillion in 2014, and forecasts expect another $300 billion in growth by 2018 according to Thomson Reuters. If you watch TV, read magazines, or even go out in public, this probably doesn’t surprise you. We are constantly bombarded with advertisements for various drugs. In an industry dominated by big money and marketing, it can be hard for small-cap companies to thrive. There are a few approaches, though, that can help smaller companies succeed: 1. Create a ground-breaking product that cannot be copied 2. Partner with a larger pharmaceutical company to help with… Read More

Global pharmaceutical sales hit a record $1 trillion in 2014, and forecasts expect another $300 billion in growth by 2018 according to Thomson Reuters. If you watch TV, read magazines, or even go out in public, this probably doesn’t surprise you. We are constantly bombarded with advertisements for various drugs. In an industry dominated by big money and marketing, it can be hard for small-cap companies to thrive. There are a few approaches, though, that can help smaller companies succeed: 1. Create a ground-breaking product that cannot be copied 2. Partner with a larger pharmaceutical company to help with marketing and distribution In today’s Project Alpha, we’ve found a company that does both. A Misunderstood Acquisition Has Left This Pharma Leader Undervalued Sucampo Pharmaceuticals (Nasdaq: SCMP) is a global biopharmaceutical company primarily focused on the Research and Development (R&D) of drugs. Its main product, AMITIZA, is the first chloride channel activator developed for the treatment of chronic constipation. It may not be the sexiest product, but the most successful drugs rarely are. Since 2006, AMITIZA, also known as lubiprostone, has been dispensed over 10 million times. Currently, it is available as a small oral gelcap taken twice a day and… Read More